Back to Search Results
Study Complete
Sponsor ID
20021635

Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Sponsor ID
20021635
Clinicaltrials.gov ID
NCT00116727
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

To systematically collect and document use patterns, effectiveness

and safety of DMARD treatments currently used in the management of rheumatoid

arthritis.

The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

Additional Study Details

Phase
N/A
Product
etanercept
Type
Observational
Masking
N/A
Enrollment
5103
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Rheumatoid Arthritis
    • Sex
    All
    Trial Dates
    Oct 2002 - Jun 2008
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Fulfillment of the 1987 American Rheumatism Association criteria for RA - Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)
    Exclusion Criteria:
    - Currently or previously enrolled in RADIUS 1 - Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol - Active infections - Known allergy to ENBREL® or any of its components - Current treatment with ENBREL® - Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy - Nursing or pregnant women